Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

S*Bio Licenses Early-Stage Cancer Drug to Tragara

publication date: Jan 21, 2009

S*BIO Pte Ltd of Singapore announced its second drug development deal this month. The company will sell a worldwide license to its early-stage cancer drug, a multi-kinase inhibitor, to Tragara Pharmaceuticals of San Diego in a transaction valued at up to $112.5 million. Two weeks ago, S*BIO optioned its JAK2 inhibitor program, including two drug candidates, to Onyx Pharmaceuticals for up to $550 million. More details...

Stock Symbols: (NSDQ: ONXX) (NYSE: NVS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital